CellSeed Inc. AI Stock Analysis
Want to see JP:7776 full AI Analyst Report?
CellSeed Inc. (7776) AI Stock Analysis
CellSeed Inc.
(TSE/TYO:7776)
The score is driven primarily by severe financial weakness: a 56.7% revenue decline, widening ¥1.1 billion net loss, and roughly ¥1 billion of annual cash burn that is rapidly eroding an equity base already down from ¥2.16 billion to ¥1.27 billion, raising the likelihood of a dilutive capital raise. Low leverage (debt-to-equity of 10.5%) provides only partial offset. Technicals reinforce the caution, with the price below all major moving averages and negative MACD. Valuation provides no support given negative earnings and no dividend. Earnings call and corporate event components were excluded due to lack of data, with their weight redistributed to the remaining factors.
CellSeed Inc. (7776) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 5.63B
- Dividend Yield
- ―
- Average Volume (3M)
- 194.07K
- Price to Earnings (P/E)
- -4.6
- Beta (1Y)
- 1.31
- Revenue Growth
- -49.43%
- EPS Growth
- -3.77%
- Country
- Japan
- Employees
- 36
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
CellSeed Inc. Business Overview & Revenue Model
Company Description
CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass ep...
CellSeed Inc. Financial Statement Overview
Summary
Financials are very weak. Revenue collapsed 56.7% to ¥83.7 million in 2025 while net losses widened to ¥1.1 billion, with operating losses exceeding 12x revenue (Income Statement score 15). Cash flow is the most critical concern: operating cash flow of -¥989 million and free cash flow of -¥1.02 billion, extending a multi-year burn exceeding ¥4 billion (Cash Flow score 12). The balance sheet is the only relative bright spot, with low debt-to-equity of 10.5% and ¥1.27 billion of equity, but that equity fell sharply from ¥2.16 billion and ROE is -87%, implying possible capital-raise needs within 1-2 years (Balance Sheet score 42).
Income Statement
15Very NegativeBalance Sheet
42NeutralCash Flow
12Very Negative| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 83.68M | 193.28M | 190.13M | 126.43M | 161.67M |
| Gross Profit | 42.75M | 110.11M | 107.16M | 61.02M | 84.04M |
| EBITDA | -1.05B | -855.49M | -836.52M | -750.00M | -905.67M |
| Net Income | -1.10B | -859.84M | -846.53M | -759.68M | -912.87M |
Balance Sheet | |||||
| Total Assets | 1.66B | 2.43B | 2.47B | 1.54B | 1.41B |
| Cash, Cash Equivalents and Short-Term Investments | 1.32B | 2.13B | 2.16B | 1.07B | 846.67M |
| Total Debt | 132.92M | 143.75M | 151.25M | 158.75M | 160.00M |
| Total Liabilities | 387.46M | 269.88M | 301.05M | 365.58M | 363.58M |
| Stockholders Equity | 1.27B | 2.16B | 2.16B | 1.18B | 1.04B |
Cash Flow | |||||
| Free Cash Flow | -1.02B | -884.47M | -801.07M | -733.60M | -908.15M |
| Operating Cash Flow | -988.98M | -866.10M | -779.43M | -718.01M | -817.15M |
| Investing Cash Flow | -26.72M | -18.37M | 56.31M | 61.73M | -110.44M |
| Financing Cash Flow | 200.30M | 855.48M | 1.81B | 881.81M | 396.88M |
CellSeed Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7776, the sentiment is Negative. The current price of 142.00 is below the 20-day moving average (MA) of 172.75, below the 50-day MA of 198.46, and below the 200-day MA of 247.94, indicating a bearish trend. The MACD of -13.88 indicates Positive momentum. The RSI at 21.80 is Positive, neither overbought nor oversold. The STOCH value of 14.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7776.
CellSeed Inc. Peers Comparison
Overall Rating
JP:709661Neutral
JP:497845Neutral
JP:777442Neutral
JP:459939Underperform
JP:459337Underperform
JP:777626Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | JPY 6.56B | 55.76 | ― | ― | 2.55% | -43.06% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | JPY 11.75B | -24.14 | ― | ― | -8.23% | -48.10% | |
| 42Neutral | JPY 26.03B | -70.06 | ― | ― | 17.05% | 10.47% | |
| 39Underperform | JPY 7.77B | -4.11 | ― | ― | ― | 4.85% | |
| 37Underperform | JPY 28.46B | -11.95 | ― | ― | -51.55% | 52.19% | |
| 26Underperform | JPY 6.07B | -4.61 | ― | ― | -49.43% | -3.77% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7776 | CellSeed Inc. | 142.00 | -152.00 | -51.70% | |
| JP:4593 | Healios KK | 198.00 | -269.00 | -57.60% | |
| JP:4599 | StemRIM Inc. | 122.00 | -157.00 | -56.27% | |
| JP:4978 | ReproCELL Inc. | 105.00 | -50.00 | -32.26% | |
| JP:7096 | StemCell Institute | 620.00 | -147.00 | -19.17% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 620.00 | 134.00 | 27.57% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026
